The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
Edward Z. Song, Xin Wang, Benjamin Philipson, Qian Zhang, Radhika Thokala, Logan Zhang, Charles‐Antoine Assenmacher, Zev A. Binder, Guo‐li Ming, Donald M. O’Rourke, Hongjun Song, Michael C. Milone
Abstract
. Overall, we demonstrated the potential of combining the IAP antagonist birinapant with CAR T cells as a novel and feasible approach to overcoming tumor antigen heterogeneity and enhancing CAR T cell therapy for GBM.
Topics & Concepts
Chimeric antigen receptorAntigenCancer researchImmunologyTumor antigenBiologyT cellImmunotherapyImmune systemCAR-T cell therapy researchNanowire Synthesis and ApplicationsVirus-based gene therapy research